David Enoch, Jeanine M. Bygott, Marie Louise Daly, J. Andreas Karas*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    76 Citations (Scopus)


    There has been a steady rise in the prevalence of resistant Gram-positive pathogens and concerns about the clinical effectiveness of glycopeptides in treating infections due to Staphylococcus aureus. Daptomycin is a novel lipopeptide antimicrobial agent with activity against Gram-positive organisms, including multi-resistant strains. It is licensed in the USA and Europe for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms at a dose of 4 mg/kg once daily. It has also been licensed in the USA for the treatment of S. aureus bacteraemia and right-sided endocarditis at 6 mg/kg once daily. It is a safe and well-tolerated antibiotic, particularly at the current dosing regimen. Antimicrobial resistance, whilst being increasingly reported, still remains relatively rare. Further studies are required to determine the role of daptomycin for the treatment of osteomyelitis and septic arthritis, as well as its use in combination therapy.

    Original languageEnglish
    Pages (from-to)205-213
    Number of pages9
    JournalJournal of Infection
    Issue number3
    Publication statusPublished - Sep 2007


    • Bacteraemia and endocarditis
    • Daptomycin
    • Gram positive infections
    • Skin and soft tissue infection


    Dive into the research topics of 'Daptomycin'. Together they form a unique fingerprint.

    Cite this